No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Background: Vorapaxar, a novel antiplatelet agent in advanced clinical development for the prevention and treatment of atherothrombotic disease, is a potent, orally bioavailable thrombin receptor antagonist selective for the protease-activated receptor 1 (PAR-1). Methods: Since race/ethnicity may af...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 68; no. 3; pp. 291 - 301 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Springer Nature
Mar2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |